TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20538692
Drug: Intravenous MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous MgSO4 infusion (80 mmol in 500 mL normal saline per day)
Study: 20538692
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL normal saline per day)
Study: 19001531
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (intensified structured counseling between patient and pharmacist)
Study: 16946665
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment preference among White patients (55%)
Study: 16946665
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment preference among White patients (46%)
Study: 16946665
Drug: Treatment preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference (unsure) for IDH patients
Study: 16946665
Drug: Treatment preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference (surgical) for IDH patients
Study: 16946665
Drug: Treatment preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference (unsure) for SpS/DS patients
Study: 16946665
Drug: Treatment preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference (surgical) for SpS/DS patients
Study: 14557432
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (500 IU)
Study: 14557432
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D (200 IU)
Study: 6424228
Drug: Low-lactose milk
Normalized name: CASEINATE/DEXTROSE/LACTOSE/MILK/MINERALS/MULTIVITAMINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose milk (500 ml)
Study: 6424228
Drug: Low-lactose milk
Normalized name: CASEINATE/DEXTROSE/LACTOSE/MILK/MINERALS/MULTIVITAMINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose milk (250 ml)
Study: 19444821
Drug: CYSTUS052 lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYSTUS052 lozenges
Study: 15855656
Drug: l-homocysteine (65.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-homocysteine (65.1 micromol/kg body wt)
Study: 9262275
Drug: Long-term pituitary
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term pituitary desensitization followed by gonadotrophin therapy, oocyte retrieval and embryo transfer (group 1)
Study: 9262275
Drug: Laparoscopic ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic ovarian electrocautery after pituitary desensitization followed by gonadotrophin therapy, oocyte retrieval and embryo transfer (group 2)
Study: 8328096
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (25 mg lidocaine and 25 mg prilocaine per gram of cream)
Study: 341951
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg four times daily)
Study: 10092259
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 7 days
Study: 10092259
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment and placebo groups
Study: 7762516
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment for 6 months
Study: 2102716
Drug: 40 mg/iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/iv of metoclopramide (Group A)
Study: 2102716
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone (Group B)
Study: 2102716
Drug: 2 mg/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/oral of lorazepam, 125 mg/iv methylprednisolone, and 1 mg/kg/oral of metoclopramide (Group C)
Study: 22943928
Drug: Micafungin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin at therapeutic dose (300 mg/body)
Study: 22943928
Drug: Micafungin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin at prophylactic dose (150 mg/body)
Study: 22943928
Drug: Micafungin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin at lower prophylactic dose (50 mg/body)
Study: 16023303
Drug: Ceftazidime continuous
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime continuous infusion (60 mg/kg/day following a 20 mg/kg loading dose)
Study: 16023303
Drug: Ceftazidime intermittent
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime intermittent administration (20 mg/kg every 8 hours)
Study: 10348466
Drug: L-dopa/carbidopa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/carbidopa (750 mg per day)
Study: 10348466
Drug: L-selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selegiline (10 mg per day)
Study: 8611072
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 50 mg
Study: 2157983
Drug: Aerosolized amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized amiloride (5 mmol per liter; 3.5 ml four times daily)
Study: 6368246
Drug: azimexon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: azimexon (3 X 600 mg) added to chemotherapy
Study: 8649942
Drug: Hypovolemic state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypovolemic state (before therapy)
Study: 8649942
Drug: Two-week anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week anticoagulant treatment (dicumarol therapy)
Study: 24873720
Drug: Davunetide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Davunetide (30 mg twice daily, intranasally)
Study: 10714728
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL (25 mg once per day for NYHA class II or 12.5 mg once per day for NYHA class III or IV, titrated up to 200 mg once per day)
Study: 23087948
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (dosage not specified, but mentions up to 10 g/day and 5 g/day as safe)
Study: 23087948
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (megadose therapy)
Study: 23087948
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (up to 5 g/day)
Study: 3816292
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cimetropium bromide
Study: 3816292
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cimetropium bromide
Study: 31992403
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (MAD and CPAP)
Study: 25246305
Drug: Oral dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexmedetomidine 2 µg/kg (Group D1)
Study: 25246305
Drug: Oral dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexmedetomidine 3 µg/kg (Group D2)
Study: 25246305
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate 50 mg/kg (Group C1)
Study: 25246305
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate 100 mg/kg (Group C2)
Study: 21697250
Drug: Cholecalciferol (4,000-40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to 10,000 IU/d
Study: 17302076
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Study: 17302076
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine plus clonidine, continuous infusion 10 mL x h(‐1)
Study: 17302076
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Study: 17302076
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine plus clonidine, PCA system 5 mL every 30 minutes
Study: 17302076
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Study: 17302076
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine plus clonidine, continuous infusion 5 mL h x (‐1) plus PCA 2.5 mL every 30 minutes
Study: 12699211
Drug: Monthly physician
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly physician visits
Study: 12699211
Drug: Semiannual physician
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semiannual physician visits and monthly nurse phone calls
Study: 10849265
Drug: kurorinone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: kurorinone 400 mg daily for 3 months
Study: 10849265
Drug: interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: interferon-alpha (IFN-alpha) 3 million units daily for 1 month, every other day for 2 months for 3 months
Study: 8256707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other antiarrhythmic drug therapy)
Study: 28612668
Drug: Melatonin 20
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 20 mg as a single dose
Study: 28612668
Drug: Antibiotics only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics only (Control)
Study: 27481077
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 µg/Fluticasone 500 µg combination (SF Group)
Study: 27481077
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg (T Group)
Study: 23518801
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (PE)
Study: 18996241
Drug: Therapy Assistant
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy Assistant WREX
Study: 16478747
Drug: MDM2-SNP309 (T/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDM2-SNP309 (T/G or G/G genotype)
Study: 16478747
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between T/T genotype and MDM2-SNP309 (T/G or G/G genotype)
Study: 3063045
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg i.v. and a supplementary 0.025 mg/kg every second min until sleep or dysarthria, followed by paracervical blockade with 1% mepivacaine 10 ml on each side of the portio
Study: 3063045
Drug: Fentanyl 2.5
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2.5 micrograms/kg and thiopentone 2 mg/kg i.v. with supplementary thiopentone 50 mg every 15 s until loss of the eyelid reflex, maintained with nitrous oxide in oxygen 2/1 and supplementary thiopentone 50 mg as required
Study: 31470005
Drug: Subcutaneous vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous vedolizumab 108 mg every 2 weeks
Study: 31470005
Drug: Intravenous vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous vedolizumab 300 mg every 8 weeks
Study: 31470005
Drug: Subcutaneous vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous vedolizumab
Study: 28479255
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied every night before surgery
Study: 28479255
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel applied once before surgery
Study: 28479255
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel
Study: 28479255
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 5% and clindamycin 1.2% (BPO/C) gel with >1 application
Study: 22653374
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention (daily education about sitting correctly and video demonstrations of exercises)
Study: 21212755
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and antioxidants (vitamins E+C)
Study: 19720877
Drug: PH-797804 (N-phenyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH-797804 (N-phenyl pyridinone p38 MAP kinase inhibitor)
Study: 17251533
Drug: Interferon beta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b treatment
Study: 17251533
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti‐MOG and anti‐MBP antibodies
Study: 15482993
Drug: Iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 400 mg ml(‐1) (98 ml, injection rate 5 ml s(‐1))
Study: 15482993
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 mg ml(‐1) (130 ml, injection rate 5 ml s(‐1))
Study: 9757156
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 15 ng/kg body weight/min urodilatin
Study: 9757156
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 22.5 ng/kg body weight/min urodilatin
Study: 2114782
Drug: Immediate, prehospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate, prehospital treatment initiation with rt-PA (recombinant tissue-type plasminogen activator)
Study: 2114782
Drug: Delayed, in-hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed, in-hospital treatment initiation with rt-PA
Study: 29283786
Drug: Topical Dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dexamethasone 1% (Group DEX)
Study: 26622431
Drug: Low-dose 90Sr-90Y
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 90Sr-90Y therapy combined with 0.5% timolol maleate solution
Study: 26622431
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline with identical dose of 90Sr-90Y
Study: 11220420
Drug: Pancuronium for
Normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium for both doses (Group PP)
Study: 7950181
Drug: No. 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: No. 90 Dasheng Jiangya (DSJY) oral liquid
Study: 27065308
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education (NEd) using Health Belief Model (HBM), provided twice monthly for 6 months to the intervention group (n = 80)
Study: 22961605
Drug: Acupuncture (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (AC) administered in 20 sessions over 10 weeks
Study: 22961605
Drug: Tanacetum (TAN)
Normalized name: Tanacetum cinerariifolium flower
DrugBank: Tanacetum cinerariifolium flower (DB10975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanacetum (TAN) at 150 mg/day
Study: 22961605
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (AC+TAN)
Study: 16167916
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day)
Study: 12763376
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg) for 52 weeks
Study: 8843176
Drug: Urapidil 60
Normalized name: urapidil 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 60 mg twice per day
Study: 8843176
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once per day
Study: 1321894
Drug: Half-dose chemotherapy
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose chemotherapy (50% dose reduction of all chemotherapeutic agents)
Study: 1321894
Drug: Full-dose chemotherapy
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose chemotherapy (in older children)
Study: 24810491
Drug: Early ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ART (starting after 2 weeks of tuberculosis treatment)
Study: 24810491
Drug: Delayed ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed ART (placebo, then starting ART at the end of 6 months of tuberculosis treatment)
Study: 21822762
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training (PT) added to antipsychotic medication
Study: 21822762
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication plus PT
Study: 11803730
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg/day
Study: 9667265
Drug: Thoracic radiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiation therapy starting on day 1 of chemotherapy (arm I)
Study: 9667265
Drug: Thoracic radiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiation therapy starting on day 64 of chemotherapy (arm II)
Study: 7830803
Drug: New biscuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: New biscuit (25 biscuits of 15.5 g each in 2 weeks)
Study: 2974715
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of cilazapril and propranolol
Study: 334185
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of aspirin
Study: 27655517
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral health care (POHC) and Mucosamin® during recovery after transplantation
Study: 20829713
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (O) 10 mg once-daily, with possible dose increase to 40 mg
Study: 20829713
Drug: Ramipril (R)
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril (R) 2.5 mg once-daily, with possible dose increase to 10 mg
Study: 18533736
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination therapy with statins (e.g., niacin/lovastatin, ezetimibe/simvastatin, amlodipine/atorvastatin)
Study: 18533736
Drug: Aspirin/pravastatin
Normalized name: ASPIRIN/PRAVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/pravastatin
Study: 15919088
Drug: 1000 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 microg of rectal misoprostol administered by traditional birth attendants (TBAs) in the intervention area.
Study: 15919088
Drug: Non-intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intervention group (no misoprostol treatment, referred to nearest facility).
Study: 14655926
Drug: 2.5-mg slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mg slow-release melatonin
Study: 14655926
Drug: 10-mg melatonin
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg melatonin
Study: 6144462
Drug: Diazepam 5.0
Normalized name: DIAZEPAM 5.0 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5.0 mg
Study: 6144462
Drug: Lorazepam (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (various doses)
Study: 30276500
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg (CM)
Study: 22474401
Drug: Nifedipine-telmisartan combination
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine-telmisartan combination treatment
Study: 21313903
Drug: pethidine +
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine + ketamine (5 mg pethidine and 0.25 mg kg(‐1) ketamine)
Study: 21313903
Drug: pethidine +
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine + placebo (10 mg pethidine and NS)
Study: 18037745
Drug: Transthoracic Doppler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transthoracic Doppler echocardiography with intravenous administration of adenosine (0.16 mg.kg(‐1).min(‐1))
Study: 11111290
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) in addition to relief of weightbearing structures (Gr. II)